Zymeworks Inc. (ZYME)
| Market Cap | 1.79B |
| Revenue (ttm) | 134.48M |
| Net Income (ttm) | -63.43M |
| Shares Out | 74.84M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,163,527 |
| Open | 24.00 |
| Previous Close | 18.52 |
| Day's Range | 22.55 - 26.19 |
| 52-Week Range | 9.03 - 26.19 |
| Beta | 1.31 |
| Analysts | Strong Buy |
| Price Target | 22.00 (-7.95%) |
| Earnings Date | Nov 6, 2025 |
About ZYME
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprisin... [Read more]
Financial Performance
In 2024, Zymeworks's revenue was $76.30 million, an increase of 0.38% compared to the previous year's $76.01 million. Losses were -$122.70 million, 3.39% more than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $22.0, which is a decrease of -7.95% from the latest price.
News
Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise
Jazz Pharmaceuticals plc and Zymeworks Inc. announced positive topline phase 3 results for Ziihera in HER2-positive gastroesophageal adenocarcinoma. Ziihera in combination with chemotherapy and in com...
Zymeworks Surges On Positive Ziihera Phase 3 Data: Expanding First-Line GEA Opportunity
Zymeworks Inc. (ZYME) surged after positive Phase 3 results for Ziihera in first-line HER2-positive gastroesophageal adenocarcinoma, expanding its FDA-approved indications. ZYME's partnership-driven m...
Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans
Zymeworks Inc. (NASDAQ: ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.
Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.
The companies' drug Ziihera shows clinically meaningful benefits for patients with gastroesophageal adenocarcinoma.
Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
VANCOUVER, British Columbia, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...
Zymeworks Inc. (ZYME) Q3 2025 Earnings Call Transcript
Zymeworks Inc. ( ZYME) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Shrinal Inamdar - Director of Investor Relations Leone Patterson - Executive VP and Chief Business & Fin...
Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC Conference First patient dosed in Phase 1 clinical trial of ZW251...
Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks Inc. (ZYME) Shareholder/Analyst Call Transcript
Zymeworks Inc. (NASDAQ:ZYME) Shareholder/Analyst Call October 23, 2025 3:30 PM EDT Company Participants Sabeen Mekan - Senior Vice President of Clinical Development Stuart Barnscher Conference Call P...
Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference
VANCOUVER, British Columbia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference
Preliminary data presented at the AACR-NCI-EORTC conference will provide insights into the potential of ZW191 in patients with advanced solid tumors, including ovarian cancer, endometrial cancer, and ...
InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of prop...
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks: Despite T-Cell Engager Setback, ADC Candidates Press On
I maintain my Strong Buy rating on Zymeworks Inc., driven by its robust ADC pipeline and upcoming pivotal zanidatamab data in late 2025. ZW171 was discontinued due to on-target off-tumor toxicity, but...
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
Zymeworks Inc. ZYME on Tuesday decided to voluntarily discontinue clinical development of ZW171, a T-cell engager designed to target gynecological, thoracic, and digestive system cancers.
Zymeworks halts development of cancer drug after trial setback
Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company's goals as a standalone therapy.
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherape...
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
VANCOUVER, British Columbia, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript
Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Kenneth H. Galbraith - Chairman of the Board, CEO & President Leone D.
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
VANCOUVER, British Columbia, July 28, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
VANCOUVER, British Columbia, July 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeu...
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)
Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Ph...
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeut...